Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

BACKGROUND: No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic activity against rGB. METHODS: Adult patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Awada, Gil, Ben Salama, Laila, De Cremer, Jennifer, Schwarze, Julia Katharina, Fischbuch, Lydia, Seynaeve, Laura, Du Four, Stephanie, Vanbinst, Anne-Marie, Michotte, Alex, Everaert, Hendrik, Rogiers, Anne, Theuns, Peter, Duerinck, Johnny, Neyns, Bart
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7570224/
https://ncbi.nlm.nih.gov/pubmed/33067319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001146
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados